Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,936 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, Miller M, Shen YK, Kannan A, Li S, DeKlotz C, Papp K. Bissonnette R, et al. Among authors: miller m. N Engl J Med. 2024 Feb 8;390(6):510-521. doi: 10.1056/NEJMoa2308713. N Engl J Med. 2024. PMID: 38324484 Clinical Trial.
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
Blauvelt A, Tsai TF, Langley RG, Miller M, Shen YK, You Y, Yang YW, Papp KA, Puig L. Blauvelt A, et al. Among authors: miller m. J Am Acad Dermatol. 2022 Apr;86(4):827-834. doi: 10.1016/j.jaad.2021.11.004. Epub 2021 Nov 17. J Am Acad Dermatol. 2022. PMID: 34798201 Clinical Trial.
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study.
Kimball AB, Podda M, Alavi A, Miller M, Shen YK, Li S, Xu Y, Han C, Fakharzadeh S, Yang YW, DePrimo S, Munoz E, Chen Y, Passeron T, Papp K. Kimball AB, et al. Among authors: miller m. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2098-2108. doi: 10.1111/jdv.19252. Epub 2023 Jun 27. J Eur Acad Dermatol Venereol. 2023. PMID: 37317022 Clinical Trial.
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM. Reich K, et al. Among authors: miller m. Br J Dermatol. 2021 Dec;185(6):1146-1159. doi: 10.1111/bjd.20568. Epub 2021 Sep 8. Br J Dermatol. 2021. PMID: 34105767 Clinical Trial.
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
Blauvelt A, Lebwohl M, Langley RG, Rowland K, Yang YW, Chan D, Miller M, You Y, Yu J, Thaҫi D, Foley P, Papp KA. Blauvelt A, et al. Among authors: miller m. J Am Acad Dermatol. 2023 Aug;89(2):274-282. doi: 10.1016/j.jaad.2023.03.035. Epub 2023 Apr 3. J Am Acad Dermatol. 2023. PMID: 37019386 Free article.
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, Kollmeier AP, Miller M, Wang Y, Li S, Chakravarty SD, Chan D, Shawi M, Yang YW, Thaҫi D, Rahman P. Strober B, et al. Among authors: miller m. Drug Saf. 2024 Jan;47(1):39-57. doi: 10.1007/s40264-023-01361-w. Epub 2023 Oct 31. Drug Saf. 2024. PMID: 37906417 Free PMC article. Clinical Trial.
15,936 results
You have reached the last available page of results. Please see the User Guide for more information.